Award-Winning Excellence, Year After Year
Independent rankings and expert evaluations recognize MSK each year as a world leader in patient-centered cancer care and research.
The FDA has approved daraxonrasib, a first-of-its-kind targeted therapy for metastatic pancreatic cancer. In a landmark clinical trial led by MSK's Dr. Eileen O'Reilly, the drug doubled median survival compared with chemotherapy — offering an important new option for people facing one of the hardest-to-treat cancers.
Find Cancer Types and Conditions
- AIDS-Associated Cancers
- Acoustic Neuroma (Vestibular Schwannoma)
- Adrenal Tumors
- Anal Cancer
- Appendiceal Cancer
- Basal Cell Carcinoma
- Benign Blood Disorders
- Bile Duct Cancer (Cholangiocarcinoma)
- Bladder Cancer
- Bone Cancer
- Brain Metastases
- Brain Tumors & Brain Cancer
- Breast Cancer
- Cancer of Unknown Primary Origin
- Central Nervous System (CNS) Lymphoma
- Cervical Cancer
- Colon Cancer
- Colorectal Cancer
- Desmoplastic Small Round Cell Tumors (DSRCT)
- Esophageal Cancer
- Gallbladder Cancer
- Ewing Sarcoma
- Gastrointestinal Neuroendocrine Tumors
- Genitourinary Cancer
- Gestational Trophoblastic Disease
- Glioma
- Germ Cell Tumors and Sex Cord Stromal Tumors
- Graft-Versus-Host Disease (GVHD)
- Gynecologic Cancer
- Head & Neck Cancers
- Histiocytosis
- Kaposi Sarcoma
- Kidney Cancer (Renal Cell Cancer)
- Leukemia and Other Blood Cancers
- Liver Cancer
- Liver Metastases (Secondary Liver Cancer)
- Lung Cancer
- Lymphoma
- Male Breast Cancer
- Liver Tumors in Children
- Melanoma
- Merkel Cell Carcinoma
- Mouth (Oral) Cancer
- Multiple Myeloma
- Myelodysplastic Syndrome (MDS)
- Nasal Cavity and Sinus Cancers
- Neuroblastoma
- Neurofibromatosis and Schwannomatosis
- MSK Kids Rare Tumors Program
- Ovarian Cancer
- Pancreatic Cancer
- Pancreatic Cysts
- Peritoneal & Pleural Mesothelioma Cancers
- Pediatric Sarcomas
- Pituitary Gland Tumors & Adenomas
- Osteosarcoma
- Primary Brain Tumors
- Pediatric Carcinomas and Other Rare Solid Tumors
- Primary Hyperparathyroidism and Parathyroid Tumors
- Prostate Cancer
- Rare Blood Disorders
- Pediatric Brain Tumors
- Rectal Cancer
- Pediatric Leukemias
- Salivary Gland Cancer
- Pediatric Lymphomas
- Skin Cancer
- Skull Base Tumors
- Soft Tissue Sarcoma
- Spine Tumors & Spinal Cancer
- Squamous Cell Carcinoma
- Stomach (Gastric) Cancer
- Rhabdomyosarcoma
- Testicular Cancer (Germ Cell Tumors)
- Throat Cancer
- Thymoma & Other Thymic Tumors
- Thyroid Cancer
- Retinoblastoma
- Tongue Cancer
- Tracheal Diseases
- Uterine (Endometrial) Cancer
- Uterine Sarcoma
- Wilms' Tumor and Other Kidney Tumors in Children
Here for Every Step Forward
At MSK, you will never navigate cancer alone. Our Care Teams will help guide you through each step.
Innovating with Impact
Discoveries made in our labs lead to new treatments that improve outcomes and change lives for patients at MSK and around the world.
The Future of Oncology
Training the next generation of leaders in cancer care and research is central to our mission. MSK provides hands-on mentorship and world-class education that prepares emerging scientists and clinicians for the future.
MSK News and Discoveries
Memorial Sloan Kettering Cancer Center (MSK) was ranked the top cancer center in the Northeast and New York metropolitan area, the No. 2 cancer hospital in the nation, and the No. 1 hospital for urology care in the 2026–27 U.S. News & World Report Best Hospitals rankings. MSK has remained among the nation's top two cancer centers for more than 35 years.
MSK researchers identified a protein called ZFP36L2 that acts as a critical "molecular switch" controlling how gut cells repair themselves after injury — a mechanism that colorectal cancer hijacks to spread to other organs. The findings could point toward new treatments that exploit cancer cells' dependence on this protein to stop metastasis or overcome treatment resistance.
Read how prostate cancer screening saved a man's life and inspired his activism for cancer awareness in the Black community.
1Based on Medicare patient data adjusted survival rate for all cancers combined when compared to all National Cancer Institute (NCI)-Designated Comprehensive Cancer Centers.